These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28144231)

  • 1. Non-Genomic Actions of the Androgen Receptor in Prostate Cancer.
    Leung JK; Sadar MD
    Front Endocrinol (Lausanne); 2017; 8():2. PubMed ID: 28144231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of androgen receptor variants in prostate cancer.
    Zhu Y; Luo J
    Asian J Urol; 2020 Jul; 7(3):251-257. PubMed ID: 33024700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Androgen Receptor in Prostate Cancer: A Review.
    Fujita K; Nonomura N
    World J Mens Health; 2019 Sep; 37(3):288-295. PubMed ID: 30209899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer.
    Case TC; Merkel A; Ramirez-Solano M; Liu Q; Sterling JA; Jin R
    Transl Oncol; 2021 Nov; 14(11):101213. PubMed ID: 34461557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in the development of protein-protein interaction inhibitors targeting androgen receptor-coactivator binding in prostate cancer.
    Biron E; Bédard F
    J Steroid Biochem Mol Biol; 2016 Jul; 161():36-44. PubMed ID: 26196120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An imaging agent to detect androgen receptor and its active splice variants in prostate cancer.
    Imamura Y; Tien AH; Pan J; Leung JK; Banuelos CA; Jian K; Wang J; Mawji NR; Fernandez JG; Lin KS; Andersen RJ; Sadar MD
    JCI Insight; 2016 Jul; 1(11):. PubMed ID: 27525313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation.
    Liao RS; Ma S; Miao L; Li R; Yin Y; Raj GV
    Transl Androl Urol; 2013 Sep; 2(3):187-96. PubMed ID: 26816736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of androgen receptors by NaAsO
    Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
    Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer.
    Narayanan R
    Asian J Urol; 2020 Jul; 7(3):271-283. PubMed ID: 32742927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.
    Shafi AA; Putluri V; Arnold JM; Tsouko E; Maity S; Roberts JM; Coarfa C; Frigo DE; Putluri N; Sreekumar A; Weigel NL
    Oncotarget; 2015 Oct; 6(31):31997-2012. PubMed ID: 26378018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges.
    Kita Y; Goto T; Akamatsu S; Yamasaki T; Inoue T; Ogawa O; Kobayashi T
    Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30248934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
    Thamilselvan V; Menon M; Thamilselvan S
    Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer.
    Sadar MD
    World J Urol; 2012 Jun; 30(3):311-8. PubMed ID: 21833557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.
    Zarif JC; Lamb LE; Schulz VV; Nollet EA; Miranti CK
    Oncotarget; 2015 Mar; 6(9):6862-76. PubMed ID: 25730905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.